Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR5287)

Aquitaine Institute for Cognitive and Integrative Neuroscience

Université de Bordeaux

Zone nord Bat 2 2ème étage
146, rue Léo Saignat
33076 Bordeaux cedex


Supervisory authorities

CNRS Ecole Pratique des Hautes Etudes Université de Bordeaux

Our partners

Neurocampus Unitéde Formation de Biologie


GDR Robotique GDR Mémoire GDR Multi-électrodes


Home > Teams > Brain Molecular Imaging (J. BADAUT)


by Lamare Frederic - published on , updated on

Long-term evaluation of the molecular changes after early brain injury

Research axis:

Several brain disorders still lack appropriate biomarkers to permit early diagnosis, prognostic assessment and clinical evaluation of the efficacy of new treatments. This question is critical for mild traumatic brain injury, which is known to induce long-term brain disorders by increasing the risk of Alzheimer’s disease and other neurodegenerative conditions, the vulnerability to drug addiction, and by significantly decreasing the life span of the patient. Moreover, clinical and experimental evidence demonstrates the emergence of cognitive dysfunction over time.

Unfortunately, mild TBI is defined by the absence of any changes using traditional neuroimaging techniques (CT scan and MRI with T2 WI and DWI) and its diagnosis is supported uniquely by the verbal report of the patient. This diagnostic issue makes it difficult to follow injured patients over time and to deliver appropriate treatment. Therefore, there is an important societal need to have new biomarkers to follow over the long-term the evolution of injury after initial trauma, in order to have develop treatments as well as to understand the pathophysiology of these conditions using new pre-clinical models that provide a unique integrative approach from bench to bedside

Scientific expertise:

1) Animal models for brain injuries (traumatic brain injury and infection)
2) Histology and immunohistochemistry
3) Chemical biology
4) Neuroimaging
5) Chemical Neuroglycobiology
6) Biomarkers


1) Development of juvenile TBI (jTBI) model and characterization of the longterm changes in neurovascular unit along neurodegenerative process and cognitive dysfunctions after jTBI.

2) Development and test of combination therapy in juvenile TBI.

3) Sepsis/bacteremia-associated encephalopathy and neuroinflammation

4) Assessment and modeling of the neuroinflammation

5) Development of new biomarkers, Chemical Neuroglycobiology and Complex glycans in brain disorders